Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients
ConclusionCollectively, the results of these pharmacokinetic analyses support the use of the same dose of the 3D regimen for Asian and Western patients.Clinicaltrials.govNCT02534870, NCT02517515, NCT02517528.
Source: European Journal of Drug Metabolism and Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research
More News: China Health | Cirrhosis | Drugs & Pharmacology | Hepatitis | Hepatitis C | History of Medicine | Norvir | South Korea Health | Taiwan Health | USA Health